Probiotics and Autoprobiotics in the Treatment of Experimental Vaginitis

The wide prevalence of inflammatory vaginal diseases in women of different ages, a significant deterioration in the quality of life due to their presence, as well as an adverse effect on conception and the course of pregnancy make the search for more efficient and safe therapy of vaginitis an urgent issue. The article presents the results of experimental staphylococcal vaginitis treatment with probiotics and autoprobiotics in rat models, including hormonized animals after ovariectomy. The effectiveness of topical application of the probiotic strain E. faecium L3 in rats has been confirmed. The probiotic proved to be effective both in rats with a hormonized cycle and in rats with preserved ovaries. Among the tested autoprobiotic and homologous (rat) strains, the elimination of staphylococci occurred faster after the introduction of bifidobacterial. However, lactobacilli are more reliable in protection against the recurrence of infection. At the same time, homologous strains of both lactobacilli and bifidobacteria contribute to faster elimination of the pathogen compared to autostamps.

1. Ling Z., Liu X., Chen X., Zhu H., Nelson K., Xia Y., Li L. et al. Diversity of cervicovaginal microbiota associated with female lower genital tract infections. Microbial Ecol. 2011; 61 (3): 704–714. doi: 10.1007/s00248-011-9813-z.

2. Rishhuk S., Punchenko O.,Malysheva A. Endogennaya mikrobiota vlagalishha i eyo regulyacziya. Byulleten` Orenburgskogo Nauchnogo Czentra. 2013; 4 (15). (in Russian)

3. Punchenko O., Bereznitskaya E, Ermolenko E. Female genital microbiota: health, pathology, ways of correction. Akusherstvo i Ginekologiya. 2021; 3: 18–24. https://doi.org/10.18565/aig.2021.3.18-24. (in Russian)

4. Buck G. Diversity of the human vaginal microbiome. J Bacteriol Parasitol. 2014; 05 (04): 5.

5. Damarad A.L., Gonchar O.A. Diagnostika bakterial'nogo vaginoza i aerobnogo vaginita metodom amplifikacii nukleinovyh kislot v rezhime real'nogo vremeni (PCR). Dermatovenerologiya. Kosmetologiya. 2016; 2 (1): 60–65. (in Russian)

6. Rossijskoe obshchestvo akusherov-ginekologov, FGBU «Nauchnyj centr akusherstva, ginekologii i perinatologii imeni akademika V. I. Kulakova» Ministerstva zdravoohraneniya Rossijskoj Federacii. Federal'nye klinicheskie rekomendacii. Diagnostika i lechenie zabolevanij, soprovozhdayushchihsya patologicheskimi vydeleniyami iz polovyh putej zhenshchin. 2019; 57. (in Russian).

7. Rubins A. Bacterial vaginosis. Sexually Transmitted Infections and Sexually Transmitted Diseases. 2011; 203–206.

8. Bautista C., Wurapa E., Sateren W., Morris S., Hollingsworth B., Sanchez J. Bacterial vaginosis: a synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections. Mil Med Res. 2016; 3: 4. doi: 10.1186/s40779-016-0074-5.

9. Tan H., Fu Y., Yang C., Ma J. Effects of metronidazole combined probiotics over metronidazole alone for the treatment of bacterial vaginosis: a meta-analysis of randomized clinical trials. Arch Gynecol Obstet. 2017; 295 (6): 1331–1339. doi: 10.1007/s00404-017-4366-0.

10. Kolaček S., Hojsak I., Berni Canani R., Guarino A., Indrio F., Orel R. et al. Commercial probiotic products: a call for improved quality control. A position paper by the ESPGHAN working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr. 2017; 65: 117–24. doi: 10.1097/MPG.0000000000001603.

11. De Seta F., Parazzini F., De Leo R., Banco R., Maso G., De Santo D. et al. Lactobacillus plantarum P17630 for preventing Candida vaginitis recurrence: a retrospective comparative study. Eur J Obstet Gynecol Reprod Biol. 2014; 182: 136–139. doi: 10.1016/j.ejogrb.2014.09.018.

12. Buggio L., Somigliana E., Borghi A., Vercellini P. Probiotics and vaginal microecology: fact or fancy? BMC Womens Health. 2019; 19 (1). doi: 10.1186/s12905-019-0723-4.

13. Ma L., Su J., Su Y., Sun W., Zeng Z. Probiotics administered intravaginally as a complementary therapy combined with antibiotics for the treatment of bacterial vaginosis: a systematic review protocol. BMJ Open. 2017; 7 (10): e019301. doi: 10.1136/bmjopen-2017-019301.

14. Buggio L., Somigliana E., Borghi A., Vercellini P. Probiotics and vaginal microecology: fact or fancy? BMC Womens Health. 2019; 19 (1): 25–31. doi: 10.1186/s12905-019-0723-4.

15. Kyrgiou M., Mitra A., Moscicki A. Does the vaginal microbiota play a role in the development of cervical cancer? Trans Res. 2017; 179: 168–182. doi: 10.1016/j.trsl.2016.07.004.

16. Brotman R., He X., Gajer, P., Sharma E., Mongodin E.F., Ravel J. et al. Association between cigarette smoking and the vaginal microbiota: a pilot study. BMC Infect Dis. 2014; 28 (14): 471–482. doi: 10.1186/1471-2334-14-471.

17. Gille C., Böer B., Marschal M., Urschitz M.S., Heinecke V., Hund V. et al. Effect of probiotics on vaginal health in pregnancy. EFFPRO, a randomized controlled trial. Am J Obstet Gynecol. 2016; 215 (5): 608–615. doi: 10.1016/j.ajog.2016.06.021.

18. Li C., Wang, T., Li, Y., Zhang T., Wang Q., Heet J. al. Probiotics for the treatment of women with bacterial vaginosis: A systematic review and meta-analysis of randomized clinical trials . Eur J Pharmacol. 2019; 1–39. doi: 10.1016/j.ejphar.2019.172660.

19. Russo R., Karadja E., De Seta F. Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. Beneficial microbes. 2019; 10 (1): 19–26. doi: 10.3920/BM2018.0075.

20. Homayouni A., Bastani P., Ziyadi S. et al. Effects of probiotics on the recurrence of bacterial vaginosis: a review. J Lower Genit Tract Dis. 2014; 18: 79–86. doi: 10.1097/LGT.0b013e31829156ec.

21. Zommiti M., Chevalier S., Feuilloley M.G.J., Connil N. Special issue enterococci for probiotic use: safety and risk: Microorganisms. 2022; 10 (3): 604. doi: 10.3390/microorganisms10030604.

22. Ermolenko E., Abdurasulova I., Tarasova E., Leontieva G., Kotyleva M., Kramskay L. et al. Features of the probiotic enterococci influence on the immune system in experimental models of multiple sclerosis and intestinal dysbiosis. Proceedings. 8th Probiotics. Prebiotics & New foods. 2015; 72.

23. Averina O.V., Ermolenko E.I., Ratushniy A.Yu., Tarasova E.A., Borschev Yu.Yu.,Leontieva G.F. et al. Influence of probiotics on cytokine production in the in vitro and in vivo systems. Medical Immunology. 2015; 17 (5). http://dx.doi.org/10.15789/1563-0625-2015-5-443-454. (in Russian)

24. Suvorov A.N., Ermolenko E.I., Alechina G.A., Chernysh A., Karaseva F., Pierr D. Enterococcus as probiotics: what is the advantage? Nutrafoods. 2019; 1: 17–25. http://dx.doi.org/10.17470/NF-019-0003.

25. Abdurasulova I.N., Tarasova E.A., Ermolenko E.I., Kudryavcev I.V., Serebryakova M.K., Bol'shakova K.O., Bisaga G.N., Skulyabin D.I., Klimenko V.M. Enterococcus faecium L3 korrektiruet mikrobiotu kishechnika i moduliruet immunnye funkcii u krys s eksperimental'nym allergicheskim encefalomielitom i pacientov s rasseyannym sklerozom. Materialy 2-go Vserossijskogo Kongressa s mezhdunarodnym uchastiem «RS i drugie demieliniziruyushchie zabolevaniya», YAroslavl'. 10–13 sentyabrya 2015. Zhurnal Nevrologii i Psihiatrii. 2015; 2 (8): 45. (in Russian)

26. Solov'eva O. I., Simanenkov V. I., Suvorov A. N., Ermolenko E. I., SHumihina I. A., Svirido D. A. Ispol'zovanie probiotikov i autoprobiotikov v lechenii sindroma razdrazhennoj tolstoj kishki. Eksperimental'naya i Klinicheskaya Gastroenterologiya. 2017; 7 (143). (in Russian)

27. Patent RUS №2139070 C1/ 31.03.1999. Shenderov B. F., Manvelova M. A. Patent. Sposob polucheniya autoprobiotika, soderzhashchego zhivye bifidobakterii i laktobacilly. Dostupno po: http://https://patents.google.com/patent/RU2139070C1/ru. Ssylka aktivna na 05.06.2022. (in Russian)